

CSD/BSE&NSE/2022-2023  
March 08, 2023

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: SBO change - Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

.....

This is to inform you that the Board of Directors of the Company have been informed by our Promoter Group entity - Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust), that the Significant Beneficial Owner (SBO) Mr. Subba Rao Jasti, father of Shri Venkateswarlu Jasti, Managing Director of our company has passed away on 2nd February 2023. In terms of the WILL executed by Mr. Subba Rao Jasti, the 9,980 equity shares held by him in the said promoter group entity devolved and transmitted to Mrs. Sudharani Jasti on 08<sup>th</sup> March 2023, one of the promoter of our company. Post this transmission Mrs. Sudharani Jasti becomes SBO of the listed entity.

The changes in the particulars relating to SBO will accordingly be updated in the next shareholding pattern to be filed for the quarter ended 31<sup>st</sup> March, 2023 in terms of LODR Regulations as amended.

This intimation is also being uploaded on the Company’s website at [www.suvenpharm.com](http://www.suvenpharm.com)

This is for your information and record.

Thanking you,  
Yours faithfully,  
**For Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

**Suven Pharmaceuticals Limited**